ASX Health Stocks: Race Oncology blows past dosing stage of Phase 1, targets Phase 2

ASX health stock Race Oncology has completed the dose escalation stage of its Phase 1b/2 Zantrene study into ALM ( (acute myeloid leukemia).

Hear it first

Get the latest Stockhead news delivered free to your inbox.

Email Lists

Thanks! You’re subscribed, Stockhead news is coming your way soon.